<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">There are several advantages of long-term responses in this setting, where treatment options are limited. Treatment is usually of palliative intent, and patients are often unable to tolerate combination regimens because of factors including comorbidities, age, poor performance status and cardiotoxicity from previous anthracycline therapy [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Therefore, monotherapies with good tolerability and long-term efficacy are sorely needed [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Pixantrone was designed to maintain efficacy while reducing the risk of cardiotoxicity. It is non-cross-resistant with anthracyclines and generally well tolerated with a manageable toxicity profile, making it a useful treatment option [
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR18">18</xref>].
</p>
